Royalty Pharma, an investor in royalty streams from pharmaceuticals, raised its offer to buy Elan Corp. (ELN) to as much as $12 per American depositary receipt, threatening the Irish drugmaker’s plan to embark on its own acquisitions.The formal offer ...
[Published Bloomberg - Apr 15 2013]